Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
EGLT: 5.97 (+0.21), LNCO: 10.87 (-0.44), ASPS: 33.81 (+4.37), DERM: 19.65 (+0.38), MCEP: 6.07 (-0.12), GTIM: 6.13 (-0.07), LINE: 10.93 (-0.32), ORPN: 6.25 (-0.35), NYNY: 7.89 (+0.32), POZN: 7.86 (+0.07), OTIC: 32.26 (+0.65)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pozen, Inc. - POZN
PR Newswire - Wed Dec 17, 1:24PM CST
Pomerantz LLP is investigating claims on behalf of investors of Pozen, Inc. ("Pozen" or the "Company"
POZN: 7.86 (+0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 11:46AM CST
PTRY: 36.78 (+0.28), VIP: 4.07 (-0.26), CCM: 5.87 (-0.11), HGSH: 4.60 (-0.06), CLF: 6.06 (-0.09), ASPX: 49.93 (-0.10), SN: 9.91 (-0.71), NVGN: 2.40 (-0.09), NYNY: 7.89 (+0.32), FVE: 4.03 (-0.03), DRIV: 24.49 (+0.09), SGNL: 2.22 (-0.01), RT: 6.30 (+0.10), SFY: 4.47 (-0.06), VOLC: 17.95 (+0.02), WRES: 1.66 (-0.13), SGNT: 25.58 (+0.31), BBLU: 1.15 (-0.03), POZN: 7.86 (+0.07), XNCR: 16.83 (+0.77)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 6.49 (+0.29), FRO: 2.43 (-0.01), KNDI: 12.90 (+0.99), GFI: 4.37 (+0.13), CLF: 6.06 (-0.09), NVGN: 2.40 (-0.09), ASPX: 49.93 (-0.10), DRIV: 24.49 (+0.09), SID: 2.24 (-0.08), HALO: 9.34 (+0.31), VOLC: 17.95 (+0.02), POZN: 7.86 (+0.07), ICLD: 3.00 (-0.02), TASR: 26.86 (+0.84), DGLY: 15.62 (+0.82), SBGL: 7.13 (+0.20)
Pozen receives second CRL for Yosprala, shares drop
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 7:28AM CST
POZN: 7.86 (+0.07)
POZEN's YOSPRALA(TM) Receives Complete Response Letter from The FDA
Business Wire - Wed Dec 17, 5:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that their investigational drug candidates YOSPRALA(TM) 81/40 and 325/40 (aspirin / omeprazole delayed release tablets) have received a second complete response letter (CRL) from the U.S. Food and Drug Administration (FDA). A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the new drug application (NDA) in its current form.
POZN: 7.86 (+0.07)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Pozen Inc. Is A Great Opportunity For Investors
Mix Star - at Seeking Alpha - Sat Dec 13, 1:36PM CST
POZN: 7.86 (+0.07)
5 Stocks Insiders Can't Stop Buying: Titan International and More
at The Street - Wed Dec 10, 6:00AM CST
It's important to always be monitoring insider activity but twice as important to make sure the trend of the stock matches up with the insider buying.
DO: 38.66 (-0.62), HCOM: 27.34 (+0.27), POZN: 7.86 (+0.07), GLUU: 4.07 (-0.04), TWI: 10.92 (-0.20)
How To YieldBoost Pozen To 37.5% Using Options
at The Street - Mon Dec 08, 10:32AM CST
Shareholders of Pozen Inc. looking to boost their income beyond the stock's 19.1% annualized dividend yield can sell the June 2015 covered call at the $12 strike and collect the premium based on the 90 cents bid, which annualizes to an additional...
POZN: 7.86 (+0.07)
InsiderInsights.com Daily Round Up 12/3/14: VRX, PSEC, MATR, OCIP
InsiderInsights - at Seeking Alpha - Wed Dec 03, 11:28PM CST
VRX: 140.33 (-0.22), HCOM: 27.34 (+0.27), MATR: 6.09 (+0.03), ARI: 16.86 (-0.04), RENT: 75.98 (-0.75), LLY: 70.16 (+0.42), SPB: 97.15 (-0.49), GOOG: 528.77 (-1.82), DXPE: 51.55 (-0.41), K: 67.02 (-0.22), DO: 38.66 (-0.62), OCIP: 16.16 (-0.38), NOW: 69.69 (+0.12), COF: 83.23 (-0.05), DYN: 29.42 (+0.12), TWTR: 37.61 (+0.04), POZN: 7.86 (+0.07), DATA: 88.76 (+0.04), EL: 77.39 (-0.37), PSEC: 8.59 (-0.02)
POZEN (POZN) Is Weak On High Volume Today
at The Street - Wed Dec 03, 9:06AM CST
Trade-Ideas LLC identified POZEN (POZN) as a weak on high relative volume candidate
POZN: 7.86 (+0.07)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 115.15 (+1.40), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NKTR: 15.02 (+0.23), AGN: 210.12 (+0.95), IPXL: 31.32 (+0.26), ALDR: 25.67 (+0.43), QCOR: 93.60 (+1.52), MRK: 57.46 (+0.25), TSPT: 1.70 (-0.04), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 02, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CY: 14.61 (+0.26), FBNK: 16.50 (unch), SHBI: 9.45 (+0.05), VGGL: 2.89 (+0.04), QDEL: 27.86 (-0.17), ISIG: 3.78 (+0.02), POZN: 7.86 (+0.07), PFBX: 12.97 (+0.14), IROQ: 16.83 (-0.12), ORPN: 6.25 (-0.35), OBAS: 7.04 (-0.46)
POZEN (POZN) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:05AM CST
Trade-Ideas LLC identified POZEN (POZN) as a strong on high relative volume candidate
POZN: 7.86 (+0.07)